Status:
UNKNOWN
A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Lead Sponsor:
Centro di Riferimento Oncologico - Aviano
Conditions:
Oropharyngeal Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Inclusion of new biomarkers to improve the personalized treatment approach for HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC) patients is urgently needed. Emerging evidences ...
Eligibility Criteria
Inclusion
- newly diagnosed, previously untreated, histologically confirmed stage III-IVa OPSCC, according to AJCC 7th Edition,
- managed with definitive treatment modality (either radical surgery plus adjuvant radiotherapy ± chemotherapy or definitive chemo-radiotherapy)
- minimum follow up of 2 years or who had disease recurrence within 2 years after the end of treatment.
- neoplastic lesion contains ≥ 70% neoplastic cells
Exclusion
- Patients:
- with distant metastases at diagnosis,
- who have been managed with palliative intent;
- with previous history of head and neck cancer are not eligible
Key Trial Info
Start Date :
April 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
267 Patients enrolled
Trial Details
Trial ID
NCT06138483
Start Date
April 19 2019
End Date
June 30 2025
Last Update
November 18 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro di Riferimento Oncologico (CRO), IRCCS
Aviano, Italy
2
Ospedale San Martino di Belluno - ULSS 1 Dolomiti
Belluno, Italy
3
Ospedale dell'Angelo - Mestre - Ulss 3 Serenissima
Mestre, Italy
4
Ospedale Santa Maria degli Angeli - ASFO
Pordenone, Italy